SBI Card joins hands with Apollo to launch wellness focused credit card
This one-of-its-kind premium credit card has been thoughtfully designed to address the evolving needs of today's health-conscious consumers, offering a compelling blend of healthcare savings and financial rewards. Customers can easily apply for this card digitally on the Apollo 24|7 app and opt to apply via SBI Card SPRINT, by visiting the SBI Card website SBI Card.com. Customers can also apply for the card at select Apollo Pharmacy stores.
The Apollo SBI Card SELECT cardholders are entitled to enjoy a rewarding shopping experience on transactions, including pharmacy products, health check-up packages, blood tests, and more through the Apollo 24|7 app and Apollo Pharmacy stores.
Cardholders get 10 per cent back as reward points, and additionally up to 15 per cent back as health credits, giving them a total value back of up to 25%. Reward points can be converted into Health Credits, which are redeemable across the entire product range of Apollo 24|7 App and Apollo pharmacy stores.
Apollo SBI Card SELECT card customers receive ₹ 1,500 e-gift voucher as welcome benefits, redeemable on the Apollo 24|7 app and at Apollo pharmacy stores. They are also entitled to Apollo Circle benefits that provide priority access to services and special discounts on doctor consultations, diagnostic tests and pharmacy orders on Apollo platforms.
Additionally, Apollo SBI Card SELECT card customers also get a complimentary 1-year FITPASS PRO Membership, offering access to a wide network of gyms, fitness classes, and wellness programs, across India.
Salila Pande, MD & CEO, SBI Card said, 'At SBI Card, we understand the evolving spending needs and aspirations of today's conscious consumers who are focused on good health and well-being. Our collaboration with Apollo HealthCo to introduce Apollo SBI Card SELECT card is firmly aligned with this need. By offering thoughtful healthcare benefits and valuable rewards, we aim to empower our customers to stay committed to their health and wellness goals, while enjoying varied financial benefits.'
Shobana Kamineni, executive chairperson, Apollo HealthCo said, 'With the Apollo SBI Credit Card, we're introducing a revolutionary financial product designed to seamlessly connect health and wellness with everyday living. By turning everyday spending into health investments, we're making access to care seamless, intuitive, and affordable. It's our way of saying that healthcare should be earned, saved, and accessed just as easily as any other essential. This is the future of health—and we are proud to build it with SBI Card. Together, we will be the health keeper of the nation.'
Disclaimer: Mint has a tie-up with fintechs for providing credit, you will need to share your information if you apply. These tie-ups do not influence our editorial content. This article only intends to educate and spread awareness about credit needs like loans, credit cards and credit score. Mint does not promote or encourage taking credit as it comes with a set of risks such as high interest rates, hidden charges, etc. We advise investors to discuss with certified experts before taking any credit.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
5 hours ago
- Mint
Apollo Hospitals: Simplifying corporate structure could lead to rerating
Apollo Hospitals Enterprise Ltd has decided to give its existing shareholders direct ownership of its subsidiary, Apollo Healthco Ltd. Apollo Healthco will have online, offline, retail, and wholesale pharmacy segments under one umbrella, apart from the digital consultation and treatment business of Apollo 24|7. The new entity will have nearly 667 million equity shares with a face value of ₹2 each. Apollo Hospitals' shareholders will receive 195.2 shares of Apollo Healthco for every 100 shares they hold. Apollo Healthco's listing is likely in 18-21 months. The exercise would mean that Apollo Hospitals would only have a 17.5% stake (direct plus indirect through its other subsidiaries) in Apollo Healthco, as against the earlier plan of having a 59.2% stake. Also Read: Will Torrent Pharma's big bet on JB Chemicals pay off? The two separate listed entities with dedicated leadership will allow the management teams to sharpen their focus on hospital and pharmacy businesses separately. Following the announcement, Apollo Hospitals shares touched a new 52-week high of ₹7,584.50 apiece on Tuesday. Growth potential Is there more steam left based on the separate valuation of the two businesses? Well, the answer depends on the management's ability to achieve the aspirational targets for its pharmacy business—Apollo Healthco. According to the company's presentation, Apollo Healthco's FY25 revenue (pro forma without the restructuring) was ₹16,377 crore. The management aspires for an operating revenue of ₹25,000 crore in FY27, which would mean a compound annual growth rate of 24% over the two years from FY25. This would require a significant pick-up in growth, given that the FY25 revenue had increased 19% year-on-year. Excluding Apollo 24|7 losses, the FY25 Ebitda margin was already about 6%. So, the Ebitda margin target of 7% in FY27 with operational efficiencies is achievable as it would only require Apollo 24|7 to achieve breakeven. If management is able to deliver on the aspirational numbers, it would mean an Ebitda of ₹1,750 crore in FY27. Based on the EV/ Ebitda multiple of 30x assigned by analysts at Nomura, the market capitalization attributable to Healthco is about ₹50,000 crore, as the net debt is small. Ebitda stands for earnings before interest, taxes, depreciation, and amortization. Also Read: Tech Mahindra: What can upset its apple cart Apollo Hospitals' market capitalization is now ₹1.08 trillion. So, the residual market capitalization of Apollo Hospitals, after deducting the valuation of Apollo Healthco is at ₹58,000 crore. With a net debt of around ₹5,000 crore, the implied EV/Ebitda valuation multiple of Apollo Hospitals comes to 20x based on Nomura's estimate of ₹3,150 crore Ebitda for FY26 (Apollo Health and Lifestyle having sugar clinic, dental clinic, etc. not considered due to its small size). Nomura's fair value multiple for Apollo Hospitals at 25x is higher than the derived implied multiple at 20x, implying room for upside. The growth prospects of standalone Apollo Hospitals are strong. Its future growth is likely to be largely led by capacity additions, unlike the last three years to FY25, when it relied on average revenue per occupied bed (Arpob) for growth. Apollo Hospitals had 8,025 operating beds at FY25 end. This is likely to rise by more than 50% as it plans to add nearly 4,400 beds over the next 3-4 years to address supply-side constraints, even though getting more patients is also crucial. The management expects to maintain the Ebitda margin of the hospital business at 24% even after the large expansion. Also Read: Nykaa's premium bet: A smart strategy if it delivers The hospital business has a higher Ebitda margin but is more capital-intensive in nature, whereas the pharmacy business has a lower Ebitda margin but lower capital requirements. Besides, the separate listing of Apollo Healthco would mean that the shareholders of Apollo Hospitals would have an option to choose the business they want to remain invested in.
Mint
5 hours ago
- Mint
SBI credit card rules changing from July 15: What cardholders must know
Beginning July 15, 2025, SBI Card is introducing several key changes that will influence how credit card payments are calculated and the benefits provided by the same. If you are a holder of SBI Elite, Prime, Pulse, IRCTC or other co-branded cards, it is crucial to understand what is changing and how it can impact your financial health. Revised minimum amount due calculation The minimum amount due (MAD) will now be calculated more stringently. It will include 100% of EMIs, GST, fees/ charges, financial charges, any over limits along with 2% of the remaining outstanding balance. This will consequently result in a higher minimum payment every month. Updated payment settlement order Starting July 15, 2025, SBI Cards will change the order in which payments are adjusted. Payments will first go towards GST, followed by EMIs, charges, finance charges, balance transfers, retail spends and eventually, cash advances. This step will increase interest charges if earlier dues are not cleared promptly. Air accident insurance cover discontinued Starting August 11, 2025, SBI Card will withdraw the complimentary air accident cover of ₹ 50 lakh to ₹ 1 crore provided on several co-branded cards, with partner banks such as UCO Bank, KVB, PSB along with others. Below is a quick summary of the changes that are going to be introduced by SBI Cards over the next few weeks. It is important for SBI credit card users to carefully take a note of these changes and adjust their spending and financial management accordingly. Change type Effective date Details Revised MAD calculation July 15, 2025 Now includes GST, EMI, fees, charges, and 2% of remaining balance New payment allocation rule July 15, 2025 Payments adjusted in fixed order – GST, EMI, charges, etc. Insurance benefit removed August 11, 2025 Air accident cover of ₹ 50L– ₹ 1Cr discontinued on multiple SBI cards If you are an SBI credit card holder, carefully review your card's new terms and charges: Pay more than the minimum due to avoid accumulating interest, charges and fees. Understand the new payment order so that you get a clear idea on pending dues. Check your credit cards' current benefits. Consider upgrading if it no longer fits your needs. Therefore, staying informed will assist you in avoiding surprises and manage your credit more efficiently. For any more doubts, updates and solutions visit and reach out to the respective customer service team of SBI. Disclaimer: Information above is for general awareness only. Please refer to the official SBI Card website for the latest and complete details.
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Apollo eyes 20-23% growth in new co; says restructuring to unlock value
Apollo Hospitals Enterprise Ltd (AHEL) on Tuesday said its ongoing restructuring aims to unlock the value of its omni-channel pharmacy and digital businesses, while enhancing shareholder returns. The newly formed entity is expected to achieve a year-on-year growth rate of 22–23 per cent, driven by the e-pharmacy segment and other business verticals, with a revenue target of Rs 25,000 crore by FY27. The digital health platform is also expected to break even within the next financial year. On Monday, the Chennai-based AHEL announced plans to spin off its digital health and pharmacy distribution businesses into a separate entity, with plans to list the new entity within 18 to 21 months. As part of the restructuring, the company's omni-channel pharma and digital health business, Apollo HealthCo, will first be demerged from AHEL into a new entity, following which its pharma distribution arm, Keimed, will be merged into the new company. Its current revenue stands at around Rs 16,300 crore. The company has stated plans to achieve a revenue run rate of Rs 25,000 crore by FY27 with 7 per cent EBITDA margins, said Suneeta Reddy, Managing Director, Apollo Hospitals Enterprise. After the entire restructuring process—expected to be completed by the listing of the new company by February 2027—the new entity will include the digital health platform Apollo 24/7, the offline pharmacy business of Apollo HealthCo, Keimed, and the telehealth services business. 'We are looking at a growth of around 22 per cent to 23 per cent on a year-on-year basis. In the first two quarters—Q4 and Q1 of this year—we have been able to beat that number reasonably well, and I believe that traction is on. It will primarily come from the e-pharmacy business, wherein we have started touching around Rs 165 crore to Rs 170 crore on a month-on-month basis between the platform and some of the other supporting engines,' said Madhivanan Balakrishnan, Chief Executive Officer of Apollo HealthCo. 'Both the consult business and the diagnostic business, which we work very closely with Apollo Hospitals, are also showing an uptick. There are two more lines of business which we are adding—one is insurance, which is in the early stages; that will also contribute to growth, not just as a standalone line of business but also as a feeder into our primary pharmacy and healthcare lines of business. 'And third, this year we see a reasonable amount of GMV—also more than GMV—revenue coming from our monetisation initiatives. We are reasonably confident of 20 to 25 per cent growth between both AHEL as well as Keimed once it comes through,' Balakrishnan added.
